Targeted Drug Shrinks Tumors In Hard-To-Treat Cancer

InnovationHealthcareTargeted Drug Shrinks Tumors In Hard-To-Treat CancerByWilliam A. Haseltine,Contributor.Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicineFollow AuthorJun 02, 2026, 08:58am EDTJun 02, 2026, 08:58am EDT--:-- / --:--This voice experience is generated by AI. Learn more.This voice experience is generated by AI. Learn more.Cancer cells vis - 3d rendered image, enhanced scanning electron micrograph (SEM) of cancer cell. Visual of overall shape of the cell's surface at a very high magnification. Medical research concept.gettyA new kind of cancer treatment is changing what is possible for women with uterine cancer that comes back or refuses to go away. The drug delivers chemotherapy directly to the cancer cell, then releases it inside. In a new study, this approach reduced tumor size and slowed disease progression in women whose cancer had returned after standard treatment. The findings suggest a potential new option for patients with few remaining treatments and further expand the role of antibody-drug conjugates beyond breast cancer.A Smarter Way to Deliver TreatmentAntibodies are Y-shaped proteins that the body makes to recognize and stick to specific targets, such as a virus or a cancer cell. For decades, antibodies have been used as cancer treatments because they can target tumor cells with great accuracy.More recently, antibody-drug conjugates have expanded that approach by attaching chemotherapy directly to these antibodies, turning them into targeted delivery systems. The antibody finds the cancer cell and locks on. The cell then pulls the whole package inside, and only there does it release the chemotherapy. Healthy cells are mostly spared.Standard chemotherapy floods the entire body, which is why it causes hair loss, mouth sores, and so many other side effects. The new treatment combines two components into a single molecule: an antibody and a chemothe...